A number of studies have shown that patients with schizophrenia smoke mon t
han other psychiatric patients and more than the general population. Also,
medicated schizophrenics who smoke present more positive symptoms of schizo
phrenia than non-smokers. The objective of the present study was to assess
the effect of smoking on ratings of psychopathology for 30 days following d
iscontinuation of antipsychotic medication. The subjects were 101 treatment
-resistant patients with schizophrenia who had been admitted to the inpatie
nt service of Neuroscience Research Hospital (NRH), National Institute of M
ental Health, between 1982 and 1994 to undergo studies involving discontinu
ation of antipsychotic medication. Patients were rated independently on a d
aily basis on the 212-item Psychiatric Symptom Assessment Scale (PSAS), an
extended version of the Brief Psychiatric Rating Scale (BPRS). At baseline,
ratings for Verbal Positive, Paranoia and Loss of Function were higher in
smokers (n=65) than nonsmokers (n=36), but a statistically significant diff
erence was observed only for the Verbal Positive cluster. Analysis by gende
r revealed that male non-smokers had the lowest psychopathology ratings at
baseline. There were no differences in Anxiety/depression, Behavior Positiv
e, Deficit Symptoms or Mannerisms (a measure for abnormal involuntary movem
ents). Following medication discontinuation, repeated-measure analysis demo
nstrated a 'time' effect for all the variables studied and a 'group' (smoke
rs vs. Iron-smokers) effect for Verbal Positive. Paranoia, and Loss of Func
tion. Post-hoc comparisons at individual time points showed significantly h
igher ratings for smokers at week 1 for Paranoia. No differences were obser
ved at later time points. In conclusion, at baseline, smokers had more posi
tive symptoms and were apparently more functionally impaired than non-smoke
rs. This difference was no longer evident after a 30 day medication discont
inuation period, (C) 2000 Elsevier Science B.V. All rights reserved.